Latest Myeloproliferative disease Stories
- CYT387 suppresses multiple signaling pathways, prevents proliferation and induces apoptosis in myeloma cells - - Results published in July online edition of Leukemia - MISSISSAUGA, ON, Aug. 4, 2011 /PRNewswire/ - YM BioSciences Inc.
WHITE PLAINS, N.Y., July 18, 2011 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced it has awarded two new Marshall A. Lichtman Specialized Center of Research (SCOR) grants to Frederick W.
VENLO, The Netherlands, June 15, 2011 /PRNewswire/ -- - QIAGEN in exclusive negotiations to purchase 47% initial stake in Ipsogen S.A.and then fully acquire a global leader in hematologic (blood) cancer molecular diagnostics - Ipsogen has a competitive portfolio in blood cancer testing with assays covering 15 biomarkers-including BCR-ABL and JAK2 -for patient profiling and monitoring - Many of Ipsogen's assays...
- Poster with broader update of trial results to be presented at ASCO - MISSISSAUGA, ON, May 18 /PRNewswire-FirstCall/ - YM BioSciences Inc.
MISSISSAUGA, ON, April 18 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced that updated interim anemia response data were reported for the first 60 patients enrolled in the Phase I/II trial of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis.
In response to blood cancer re-classifications by the World Health Organization, the MPD Foundation announces it is changing its name to Myeloproliferative Neoplasms (MPN) Research Foundation. Chicago, IL (PRWEB) April 4, 2011 The MPD Foundation, a patient-led foundation dedicated to the discovery of treatments and a cure for three rare blood cancers (myelofibrosis, polycythemia vera, and essential thrombocythemia) announces today a new name for the organization, which will now be known as...
- Forsooth! indeed! originally a parenthetical phrase used in repeating the words of another with more or less contempt or disdain.